Matching Placebo + Linaclotide

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Constipation

Conditions

Chronic Constipation

Trial Timeline

Aug 1, 2008 → Oct 1, 2009

About Matching Placebo + Linaclotide

Matching Placebo + Linaclotide is a phase 3 stage product being developed by Ironwood Pharmaceuticals for Chronic Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT00730015. Target conditions include Chronic Constipation.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Constipation were approved

Approved (20) Terminated (3) Active (0)
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
alefaceptAstellas PharmaApproved
AlefaceptAstellas PharmaApproved
lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00730015Phase 3Completed

Competing Products

20 competing products in Chronic Constipation

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25